Dr Reddy's gets USFDA inspection closure report fo Srikakulam unit

The plant is one of the company's three units that were served a warning letter in November 2015 for not following the prescribed operational and manufacturing quality standards

Drug major Dr Reddy's Laboratories Ltd informed the stock exchanges today that the US Food and Drug Administration (US FDA) has issued the Establishment Inspection Report (EIR) for its Active Pharmaceutical Ingredients (API) manufacturing facility at Srikakulam indicating closure of the audit. 

This facility is one of the company's three manufacturing plants that were served a warning letter by the US FDA in November 2015 for not following the prescribed operational and manufacturing quality standards.

The two other units-- Duvvada formulation